Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use [0.03%]
恩格列净在慢性肾脏病患者中的应用：早期、广泛和有信心使用证据充分吗？
Carmine Zoccali,Francesca Mallamaci
Carmine Zoccali
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis [0.03%]
恩格列净对传统和新兴的急性肾病和慢性肾病结局的影响：个体患者水平的 Meta 分析
William G Herrington,Zhaojing J Che,Rebecca Sardell et al.
William G Herrington et al.
Background: Uncertainty remains about effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on kidney outcomes in individuals with slowly progressive chronic kidney disease (eg, low albuminuria) and those at risk ...
David Beran,Amanda Adler,Carol Abidha et al.
David Beran et al.
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula [0.03%]
阿拉伯半岛第2型糖尿病流行的进化基础
Hamad Ali,Barrak Alahmad,Mohamed Abu-Farha et al.
Hamad Ali et al.
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial [0.03%]
孟朱南班特治疗肥胖和代谢综合征成人患者的疗效和安全性：一项双盲、随机、安慰剂对照的IIa期试验
Filip K Knop,George Kunos,Dror Dicker et al.
Filip K Knop et al.
Background: Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability. We aimed to evaluate the efficacy and safety of monlunabant in individuals with ...
Kishore M Gadde,Jonanne Talebloo,Daniele Piomelli
Kishore M Gadde
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Glucocorticoid-induced osteoporosis: novel concepts and clinical implications [0.03%]
糖皮质激素诱导的骨质疏松症：新概念与临床意义
Lorenz C Hofbauer,Juliet E Compston,Kenneth G Saag et al.
Lorenz C Hofbauer et al.
Despite advances in targeted therapies, treatment with glucocorticoids remains a mainstay in the management of various immune-mediated diseases. High cumulative doses of exogenous glucocorticoids lead to a spectrum of side-effects, in parti...
Prevalence of clinical obesity versus BMI-defined obesity among US adults: a cohort study [0.03%]
美国成年人临床肥胖和BMI定义的肥胖流行率：队列研究
Zhiqi Yao,Zeina A Dardari,Alexander C Razavi et al.
Zhiqi Yao et al.